G.Barekat Pharm (XTEH:BRKT1) Cash And Cash Equivalents : IRR861,629 Mil (As of Mar. 2017)

View and export this data going back to 2017. Start your Free Trial

What is G.Barekat Pharm Cash And Cash Equivalents?

G.Barekat Pharm's quarterly cash and cash equivalents stayed the same from . 20 (IRR0.00 Mil) to Mar. 2016 (IRR0.00 Mil) but then increased from Mar. 2016 (IRR0.00 Mil) to Mar. 2017 (IRR861,629.00 Mil).

G.Barekat Pharm's annual cash and cash equivalents stayed the same from . 20 (IRR0.00 Mil) to Mar. 2016 (IRR0.00 Mil) but then increased from Mar. 2016 (IRR0.00 Mil) to Mar. 2017 (IRR861,629.00 Mil).

G.Barekat Pharm Cash And Cash Equivalents Historical Data

The historical data trend for G.Barekat Pharm's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

G.Barekat Pharm Cash And Cash Equivalents Chart

G.Barekat Pharm Annual Data

Trend

Mar16

Mar17

Cash And Cash Equivalents

861,629.00

G.Barekat Pharm Semi-Annual Data
	Mar16	Mar17
Cash And Cash Equivalents	-	861,629.00

G.Barekat Pharm Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

G.Barekat Pharm (XTEH:BRKT1) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

G.Barekat Pharm Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of G.Barekat Pharm's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

G.Barekat Pharm (XTEH:BRKT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » G.Barekat Pharm (XTEH:BRKT1) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 11, 5th Alley, Bucharest Avenue, Argentina Square, Tehran, IRN

Website

http://www.bpharmed.com

G.Barekat Pharm focuses on the introduction of new pharmaceutical fields such as biotechnology, drug delivery which includes nanotechnology, slow release drugs, and new technologies for health, development of cellular molecular industries like tuberculosis, gene therapy, immunotherapy, and tissue technology.

G.Barekat Pharm (XTEH:BRKT1) Headlines

No Headlines